Rilparencel’s Moment: Why ProKidney Looks Like a High-Reward Long from Here
ProKidney's autologous renal cell therapy, rilparencel, showed statistically significant Phase 2 improvements in eGFR slope and an encouraging safety profile. With a market capitalization near $280M, an EV of roughly $185M and active short interest, the stock offers an asymmetric risk/reward to disciplined traders. This trade idea lays out an entry…